Paper36964001
Effectiveness of second booster compared to first booster and protection conferred by previous SARS-CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France.
Tamandjou C and 4 others. Vaccine, 2023. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. Effectiveness of second booster compared to first booster and protection conferred by previous SARS-CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France. Papers, record 36964001. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36964001
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Effectiveness of second booster compared to first booster and protection conferred by previous SARS-CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| COVID-19 | Major topic |
| Humans | |
| Middle Aged | |
| SARS-CoV-2 | |
| France | |
| Antigenic Variation | |
| Vaccination |
Source PubMed
References18
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36402756 | Antigenic sin of wild-type SARS-CoV-2 vaccine shapes poor cross-neutralization of BA.4/5/2.75 subvariants in BA.2 breakthrough infections. | Nat Commun | 2022 | https://conductscience.org/library/papers/36402756 | PubMed |
| 2 | 33277323 | Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM. | Sci Adv | 2021 | https://conductscience.org/library/papers/33277323 | PubMed |
| 3 | 35172051 | Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection. | N Engl J Med | 2022 | https://conductscience.org/library/papers/35172051 | PubMed |
| 4 | 36223534 | Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2. | N Engl J Med | 2022 | https://conductscience.org/library/papers/36223534 | PubMed |
| 5 | 35862287 | Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022. | MMWR Morb Mortal Wkly Rep | 2022 | https://conductscience.org/library/papers/35862287 | PubMed |
| 6 | 35662871 | Vaccine effectiveness and duration of protection against symptomatic infections and severe Covid-19 outcomes in adults aged 50 years and over, France, January to mid-December 2021. | Glob Epidemiol | 2022 | https://conductscience.org/library/papers/35662871 | PubMed |
| 7 | 34001753 | Theoretical Framework for Retrospective Studies of the Effectiveness of SARS-CoV-2 Vaccines. | Epidemiology | 2021 | https://conductscience.org/library/papers/34001753 | PubMed |
| 8 | 35793826 | Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study. | BMJ | 2022 | https://conductscience.org/library/papers/35793826 | PubMed |
| 9 | 35417631 | Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. | N Engl J Med | 2022 | https://conductscience.org/library/papers/35417631 | PubMed |
| 10 | 35699621 | Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. | Science | 2022 | https://conductscience.org/library/papers/35699621 | PubMed |
| 11 | 36239934 | Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA-Vaccinated and Nonvaccinated Individuals in Quebec, Canada. | JAMA Netw Open | 2022 | https://conductscience.org/library/papers/36239934 | PubMed |
| 12 | 34619098 | Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. | Lancet | 2021 | https://conductscience.org/library/papers/34619098 | PubMed |
| 13 | 36338436 | Extended SARS-CoV-2 RBD booster vaccination induces humoral and cellular immune tolerance in mice. | iScience | 2022 | https://conductscience.org/library/papers/36338436 | PubMed |
| 14 | 5160433 | Attributable risk percent in case-control studies. | Br J Prev Soc Med | 1971 | https://conductscience.org/library/papers/5160433 | PubMed |
| 16 | 35609888 | Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study. | BMJ | 2022 | https://conductscience.org/library/papers/35609888 | PubMed |
| 17 | 35249272 | Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. | N Engl J Med | 2022 | https://conductscience.org/library/papers/35249272 | PubMed |
| 18 | 36379401 | Diagnostic accuracy of SARS-CoV-2 rapid antigen self-tests in asymptomatic individuals in the omicron period: a cross-sectional study. | Clin Microbiol Infect | 2023 | https://conductscience.org/library/papers/36379401 | PubMed |
| 19 | 35297591 | Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron. | N Engl J Med | 2022 | https://conductscience.org/library/papers/35297591 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40028449 | All-cause mortality according to COVID-19 vaccination status: An analysis of the UK office for National statistics public data. | F1000Res | 2024 | https://conductscience.org/library/papers/40028449 | PubMed |
| 38966308 | Protection of Omicron Sub-Lineage Infection Against Reinfection with Another Omicron Sub-Lineage: Systematic Review, Meta-Analysis, and Meta-Regression - Worldwide, 2022-2023. | China CDC Wkly | 2024 | https://conductscience.org/library/papers/38966308 | PubMed |
| 38280109 | mRNA vaccine boosters and impaired immune system response in immune compromised individuals: a narrative review. | Clin Exp Med | 2024 | https://conductscience.org/library/papers/38280109 | PubMed |
| 38274635 | COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign. | Cureus | 2024 | https://conductscience.org/library/papers/38274635 | PubMed |
| 37808897 | Protection of COVID-19 Vaccination Against Hospitalization During the Era of Omicron BA.4 and BA.5 Predominance: A Nationwide Case-Control Study Based on the French National Health Data System. | Open Forum Infect Dis | 2023 | https://conductscience.org/library/papers/37808897 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36964001
GET https://conductscience.org/api/papers/v1/36964001/authors